scholarly journals Perbandingan Kadar Brain – Derived Neurotrophic Factor Pasien Psoriasis Vulgaris Dan Bukan Pasien Psoriasis Vulgaris

2019 ◽  
Vol 45 (1) ◽  
Author(s):  
Muhammad Sjahrir ◽  
Elmeida Effendy ◽  
Irma D Roesyanto
Keyword(s):  
Immunosorbent Assay ◽  
Neurotrophic Factor ◽  
Psoriasis Vulgaris ◽  
Brain Derived Neurotrophic Factor ◽  
Enzyme Linked Immunosorbent Assay

Psoriasis adalah penyakit inflamasi kronik pada kulit, dengan dugaan kuat akibat pengaruh genetik. Psoriasis memiliki karakteristik berupa gangguan pertumbuhan dan diferensiasi epidermis serta keterlibatan agen biokimiawi, imunologik, kelainan vaskular, dan sistem saraf. Keterlibatan sistem saraf pada psoriasis salah satunya diperankan oleh brain-derived neurotrophic factor (BDNF). BDNF telah dikenal luas berperan pada kondisi stres dan depresi, namun BDNF ternyata juga memilki peran menjaga homeostasis korneosit. Penelitian ini bertujuan untuk mengetahui perbedaan kadar BDNF dalam serum pasien psoriasis vulgaris dibandingkan dengan bukan pasien psoriasis vulgaris.Penelitian ini adalah penelitian analitik dengan desain potong lintang. Sebanyak 20 orang pasien psoriasis vulgaris (kasus) dan 20 orang bukan pasien psoriasis vulgaris (kontrol) ikut serta dalam penelitian ini. Pada seluruh subyek penelitian dilakukan pengambilan darah untuk dilakukan pemeriksaan kadar BDNF dalam serum dengan metode enzyme-linked immunosorbent assay (ELISA). Kadar BDNF serum yang diperoleh kemudian dinilai perbedaannya antara kelompok kasus dan kontrol dengan menggunakan uji-t independen.Hasil penelitian didapatkan kadar BDNF dalam serum pasien psoriasis vulgaris lebih rendah secara bermakna (852,99 ± 172,28 pg/ml) dibandingkan dengan bukan pasien psoriasis vulgaris (1202,37 ± 67,06 pg/ml) dengan  nilai p<0,05. Penelitian ini menyimpulkan bahwa terdapat perbedaan yang bermakna antara kadar BDNF serum pasien dan bukan pasien psoriasis vulgaris.        Kata Kunci: psoriasis vulgaris, brain-derived neurotrophic factor

scholarly journals Association between plasma levels of BDNF and the antisuicidal effects of repeated ketamine infusions in depression with suicidal ideation

2020 ◽  
Vol 10 ◽  
pp. 204512532097379
Author(s):  
Wei Zheng ◽  
Yan-Ling Zhou ◽  
Cheng-Yu Wang ◽  
Xiao-Feng Lan ◽  
Bin Zhang ◽  
...  
Keyword(s):  
Suicidal Ideation ◽  
Correlation Analysis ◽  
Immunosorbent Assay ◽  
Neurotrophic Factor ◽  
Plasma Levels ◽  
Rating Scale ◽  
Brain Derived Neurotrophic Factor ◽  
Enzyme Linked Immunosorbent Assay ◽  
Depressed Patients ◽  
Over Time

Background: This study is the first to examine the association between plasma levels of brain-derived neurotrophic factor (BDNF) and the antisuicidal effects of repeated ketamine infusions in depressed patients with suicidal ideation. Methods: Fifty-seven depressed patients with suicidal ideation received six ketamine infusions (0.5 mg/kg) during a 12 days period. Suicidality was measured with the Scale for Suicidal Ideations (SSI-part 1), item 10 of the Montgomery–Åsberg Depression Rating Scale (MADRS), and item 3 of the Hamilton Depression Rating Scale (HAMD) at baseline, 1 day after the first infusion (1 day), 1 day after the sixth infusion (13 days), and at 2 weeks after the last infusion (26 days). Plasma levels of BDNF were measured by enzyme-linked immunosorbent assay at baseline, 13 days, and 26 days. Results: Overall, 46 (80.7%) depressed patients with suicidal ideation had an antisuicidal response at 13 days. Despite a significant reduction in suicidal symptoms over time, no changes in plasma levels of BDNF were found after ketamine treatment when compared with baseline. Correlation analysis showed that no significant association was observed between the plasma levels of BDNF and the changes in the severity of suicidal symptoms as measured by SSI-part 1, item 10 of the MADRS, or item 3 of the HAMD at 1 day, 13 days, and 26 days (all p < 0.05). Conclusion: Our results indicated that plasma levels of BDNF may not serve as a biomarker for determining the antisuicidal effects of six ketamine infusions in depressed patients with suicidal ideation.

scholarly journals Correlation between Serum Brain-Derived Neurotrophic Factor Level and Depression Severity in Psoriasis Vulgaris Patients

2019 ◽  
Vol 7 (4) ◽  
pp. 583-586 ◽  
Author(s):  
Muhammad Sjahrir ◽  
Irma Damayanti Roesyanto-Mahadi ◽  
Elmeida Effendy
Keyword(s):  
Negative Correlation ◽  
Neurotrophic Factor ◽  
Psoriasis Vulgaris ◽  
Severity Index ◽  
Brain Derived Neurotrophic Factor ◽  
Enzyme Linked Immunosorbent Assay ◽  
Depression Severity ◽  
Bdnf Level ◽  
Cross Sectional ◽  
Serum Bdnf

BACKGROUND: Psoriasis vulgaris is a chronic inflammatory skin disorder that can lead to depression. There is a similarity in neurotrophic substance in the pathogenesis of psoriasis and depression; it’s called brain-derived neurotrophic factor (BDNF). BDNF level imbalance potentially affects the severity of psoriasis and depression. AIM: This study aims to know the correlation between serum BDNF level and depression severity in psoriasis vulgaris patient and also the correlation between serum BDNF level and psoriasis vulgaris severity. METHODS: This is an analytical cross-sectional study that 23 psoriasis vulgaris patients participated. All participants have performed serum BDNF level examination with enzyme-linked immunosorbent assay (ELISA). Depression severity assessed with Beck depression inventory-II (BDI-II) and psoriasis severity assessed with psoriasis area and severity index. Correlation between all variables was analysed with Spearman’s correlation test. RESULTS: Serum BDNF level and depression severity are a strongly negative correlation in psoriasis vulgaris patients (r = -0.667 with significant value p = 0.001). There is a moderate negative correlation between serum BDNF level with psoriasis vulgaris severity (r = -0.595 with significant value p = 0.003). CONCLUSION: In psoriasis vulgaris patients, a low level of serum BDNF may increase depression severity and psoriasis vulgaris severity.

scholarly journals Brain-derived neurotrophic factor levels in newly diagnosed patients with bipolar disorder, their unaffected first-degree relatives and healthy controls

BJPsych Open ◽  
2021 ◽  
Vol 7 (2) ◽  
Author(s):  
Nanna Aagaard Petersen ◽  
Marc Østergaard Nielsen ◽  
Klara Coello ◽  
Sharleny Stanislaus ◽  
Sigurd Melbye ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Neurotrophic Factor ◽  
Brain Derived Neurotrophic Factor ◽  
Enzyme Linked Immunosorbent Assay ◽  
Healthy Controls ◽  
Newly Diagnosed ◽  
First Degree Relatives ◽  
Duration Of Illness ◽  
And Gender ◽  
Medication Status

Background Brain-derived neurotrophic factor (BDNF), which facilitates neuroplasticity and synaptogenesis, may be decreased in bipolar disorder, but has not been systematically investigated in people with newly diagnosed bipolar disorder and unaffected first-degree relatives. Aims To compare BDNF levels in patients with newly diagnosed bipolar disorder, their unaffected first-degree relatives and healthy controls. Method The study investigated plasma BDNF levels in patients (n = 371) with newly diagnosed bipolar disorder, their unaffected first-degree relatives (n = 98) and healthy controls (n = 200) using enzyme-linked immunosorbent assay. We further investigated associations between BDNF levels and illness-related variables and medication status. Results BDNF levels were found to be 22.0% (95% CI 1.107–1.343) higher in patients with bipolar disorder compared with healthy controls (P < 0.001) and 15.6% higher in unaffected first-degree relatives compared with healthy controls (95% CI 1.007–1.327, P = 0.04), when adjusting for age and gender. Further, BDNF levels were positively associated with duration of illness at a trend level (P = 0.05), age (P = 0.001) and use of anti-epileptic medication (P = 0.05). Conclusions These findings suggest that BDNF levels are not decreased in the early stages of bipolar disorder and in unaffected first-degree relatives contrasting with prior findings during later stages of the illness.

scholarly journals Ramadan Fasting in Germany (17–18 h/Day): Effect on Cortisol and Brain-Derived Neurotrophic Factor in Association With Mood and Body Composition Parameters

2021 ◽  
Vol 8 ◽  
Author(s):  
Amin Riat ◽  
Abdulhadi Suwandi ◽  
Samaneh Khoshandam Ghashang ◽  
Manuela Buettner ◽  
Luqman Eljurnazi ◽  
...  
Keyword(s):  
Body Composition ◽  
Neurotrophic Factor ◽  
Venous Blood ◽  
Brain Derived Neurotrophic Factor ◽  
Enzyme Linked Immunosorbent Assay ◽  
Intermittent Fasting ◽  
Serum Samples ◽  
Ramadan Fasting ◽  
Insulin Growth Factor ◽  
Health Related

Ramadan fasting (RF) is a type of diurnal intermittent fasting. Previous studies reported the benefits of RF in healthy subjects on mood and health related to quality of life (QoL). Cortisol and brain-derived neurotrophic factor (BDNF) have been shown to play a role in mood, body composition parameters, and health-related QoL. This study aimed at elucidating the mechanism of the benefit of RF, particularly cortisol and BNDF and their association with mood and QoL. Insulin growth factor-1 (IGF-1), interleukin (IL)-8, matrix metalloproteinase (MMP)-9, and myoglobin were determined. Thirty-four healthy men and women were recruited. Serum from peripheral venous blood samples was collected at five time points: 1 week before RF (T1); mid of RF (T2), last days of RF (T3), 1 week after RF (T4), and 1 month after RF (T5). The amounts of biological mediators in the serum samples were determined by enzyme-linked immunosorbent assay (ELISA) and Luminex assays. BDNF and cortisol significantly decreased at T3 (p &lt; 0.05) and T4 (p &lt; 0.001) compared to T1, respectively. It seems the benefits of RF for mood-related symptoms are mediated by different biological mediators, particularly cortisol and BDNF.

No association of Brain-derived neurotrophic factor with striatal dopamine transporter availability in healthy subjects

2021 ◽  
Author(s):  
Hyun-Yeol Nam ◽  
Seongho Seo ◽  
Myung Jun Lee ◽  
Keunyoung Kim ◽  
In Joo Kim ◽  
...  
Keyword(s):  
Caudate Nucleus ◽  
Dopamine Transporter ◽  
Neurotrophic Factor ◽  
Healthy Subjects ◽  
Brain Plasticity ◽  
Brain Derived Neurotrophic Factor ◽  
Synaptic Function ◽  
Assay Method ◽  
Enzyme Linked Immunosorbent Assay ◽  
Serum Bdnf

Abstract Objective Brain-derived neurotrophic factor (BDNF) is a neurotrophin that plays a key role in brain plasticity, synaptic function, neuronal survival, learning, and memory formation. We aimed to investigate the association of BDNF with dopamine transporter (DAT) availabilities measured by positron emission tomography (PET) in healthy subjects. Methods Thirty-five healthy, male subjects without brain injury, neuropsychological disorders were included in this study. The emission data were acquired over 90 mins with 50 frames after injection of 18F-FP-CIT using PET. Binding potentials (BPNDs) of ventral striatum (VST), caudate nucleus, putamen were measured with the simplified reference tissue method. The serum BDNF level (pg/mL) was measured through enzyme-linked immunosorbent assay method. Results Thirty-five healthy males with a mean age of 24.4 ± 2.7 years were included in this study. Multiple regression was done to investigate the association between striatal BPNDs from VST, caudate nucleus, putamen and serum BDNF after adjusting for age. None of striatal BPNDs from VST (p=0.8450), caudate nucleus (p=0.4783), and putamen (p=0.7994) were associated with serum BDNF. Conclusion Striatal DAT availabilities measured from PET were not associated with the serum BDNF in healthy subjects.

A Pilot Study of the Use of Dexmedetomidine for the Control of Delirium by Reducing the Serum Concentrations of Brain-Derived Neurotrophic Factor, Neuron-Specific Enolase, and S100B in Polytrauma Patients

2017 ◽  
Vol 34 (8) ◽  
pp. 674-681 ◽  
Author(s):  
Yong Li ◽  
Zhi-Xin Yu ◽  
Mu-Sen Ji ◽  
Jun Yan ◽  
Yan Cai ◽  
...  
Keyword(s):  
Neurotrophic Factor ◽  
Calcium Binding ◽  
Neuron Specific Enolase ◽  
Brain Derived Neurotrophic Factor ◽  
Assessment Method ◽  
Controlled Study ◽  
Enzyme Linked Immunosorbent Assay ◽  
Common Group ◽  
Polytrauma Patients ◽  
The Common

Background: Delirium is very common among patients with polytrauma, although no suitable means exist to feasibly reduce the incidence and duration of delirium in these patients. Recent reports have suggested that continuous intravenous (IV) infusions of dexmedetomidine, rather than benzodiazepine, be administered for sedation to reduce the duration of delirium in this population. However, serum neuron-specific enolase (NSE), S100 calcium binding protein B (S100B), and brain-derived neurotrophic factor (BDNF) levels have not yet been investigated in polytrauma patients who received sedation with dexmedetomidine rather than other conventional sedatives. The aim of this study was to assess the association of blood BDNF, NSE, and S100B with the occurrence of delirium among polytrauma patients who had been sedated with dexmedetomidine. Materials and Methods: Consecutive patients were randomly assigned to 1 of 2 treatment study groups, namely the “dexmedetomidine group” or the “common group.” This case–control study included 18 patients with delirium and 34 matched controls in a 63-bed general intensive care unit (ICU). Blood samples were collected from all patients upon ICU admission, on the day when delirium was diagnosed, and on days 3 and 5 following diagnosis. The serum levels of S100B, BDNF, and NSE were determined by enzyme-linked immunosorbent assay. The sedation levels and delirium were assessed using the Richmond Agitation and Sedation Scale and the Confusion Assessment Method for the ICU. Results: The median BDNF, NSE, and S100B concentrations were significantly lower in the dexmedetomidine group than in the common group on the day when delirium was diagnosed and on the third day after delirium was diagnosed. The rate of delirium was significantly lower in the dexmedetomidine group than in the common group. There were clear differences in the BDNF, NSE, and S100B levels between the 2 groups on the fifth day after delirium was diagnosed. Conclusions: Our randomized controlled study suggests that the sedation of polytrauma patients with dexmedetomidine could help reduce the serum BDNF, S100B, and NSE levels, which appear to be associated with the occurrence of delirium in the dexmedetomidine group.

scholarly journals Plasma Exosomal Brain-Derived Neurotrophic Factor Correlated with the Postural Instability and Gait Disturbance–Related Motor Symptoms in Patients with Parkinson’s Disease

Diagnostics ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. 684
Author(s):  
Chen Chih Chung ◽  
Pai Hao Huang ◽  
Lung Chan ◽  
Jia-Hung Chen ◽  
Li-Nien Chien ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Neurotrophic Factor ◽  
Rating Scale ◽  
Brain Derived Neurotrophic Factor ◽  
Postural Instability ◽  
Gait Disturbance ◽  
Enzyme Linked Immunosorbent Assay ◽  
Motor Symptoms ◽  
Bdnf Level

Brain-derived neurotrophic factor (BDNF) is an essential neurotrophin, responsible for neuronal development, function, and survival. Assessments of peripheral blood BDNF in patients with Parkinson’s disease (PD) previously yielded inconsistent results. Plasma exosomes can carry BDNF, so this study investigated the role of plasma exosomal BDNF level as a biomarker of PD. A total of 114 patients with mild to moderate PD and 42 non-PD controls were recruited, and their clinical presentations were evaluated. Plasma exosomes were isolated with exoEasy Maxi Kits, and enzyme-linked immunosorbent assay was used to assess plasma exosomal BDNF levels. Statistical analysis was performed using SPSS version 19.0, and findings were considered significant at p < 0.05. The analysis revealed no significant differences in plasma exosomal BDNF levels between patients with PD and controls. Patients with PD with low plasma exosomal BDNF levels (in the lowest quartile) exhibited a significant association with daily activity dysfunction but not with cognition/mood or overall motor symptoms as assessed using the Unified Parkinson’s Disease Rating Scale (UPDRS). Investigation of UPDRS part III subitems revealed that low plasma exosomal BDNF level was significantly associated with increased motor severity of postural instability and gait disturbance (PIGD)-associated symptoms (rising from a chair, gait, and postural stability) after adjustment for age and sex. In conclusion, although plasma exosomal BDNF level could not distinguish patients with PD from controls, the association with PIGD symptoms in patients with PD may indicate its potential role as a biomarker. Follow-up studies should investigate the association between plasma exosomal BDNF levels and changes in clinical symptoms.

Serum Brain-Derived Neurotrophic Factor Mediates the Relationship between Abdominal Adiposity and Executive Function in Middle Age

2016 ◽  
Vol 22 (5) ◽  
pp. 493-500 ◽  
Author(s):  
Sonya Kaur ◽  
Mitzi M. Gonzales ◽  
Takashi Tarumi ◽  
Astrid Villalpando ◽  
Mohammed Alkatan ◽  
...  
Keyword(s):  
Executive Function ◽  
Neurotrophic Factor ◽  
Word Association ◽  
Brain Plasticity ◽  
Brain Derived Neurotrophic Factor ◽  
Enzyme Linked Immunosorbent Assay ◽  
Abdominal Adiposity ◽  
Increased Risk ◽  
And Performance ◽  
The Relationship

AbstractObjectives: Excessive adipose tissue, especially in the abdominal area, is associated with increased risk of dementia in older adults. However, the mechanisms underlying this relationship are poorly understood. As increased adiposity is also associated with lower circulating levels of brain-derived neurotrophic factor (BDNF), a key molecule modulating brain plasticity and neuronal regeneration, we hypothesized that the changes in cognition that occur as a result of excessive abdominal adiposity would be driven by lower levels of circulating BDNF. Methods: Fasting blood samples were obtained from 60 participants aged 40–60 years (mean±SD=52.3±5.6) and BDNF levels were assessed with an enzyme linked immunosorbent assay. Abdominal adiposity was measured using a ratio of waist circumference to hip circumference (WHR). Participants also completed a neuropsychological assessment battery to assess executive function. Statistical mediation was assessed using traditional causal steps and nonparametric bootstrapping. Results: Higher WHR was significantly associated with poorer performance on the Controlled Oral Word Association (COWA) letter fluency test (β=−0.489; p=.003) and lower levels of circulating BDNF (β=−0.345; p=.006). Linear regression and bootstrapping methods indicated that BDNF fully mediated the relationship between WHR and performance on the COWA (β=0.60; 95% confidence interval [−3.79, −0.26]). Conclusions: The relationship between higher WHR and verbal fluency was fully statistically mediated by circulating BDNF levels. The BDNF pathway is thus a useful probable mechanism through which executive function decline occurs in individuals with high abdominal adiposity. BDNF enhancing interventions (physical exercise and dietary restriction) could thus be used to improve executive function in these individuals. (JINS, 2016, 22, 1–8)

scholarly journals Effects of Brain-Derived Neurotrophic Factor on Local Inflammation in Experimental Stroke of Rat

2010 ◽  
Vol 2010 ◽  
pp. 1-10 ◽  
Author(s):  
Yongjun Jiang ◽  
Ning Wei ◽  
Juehua Zhu ◽  
Tingting Lu ◽  
Zhaoyao Chen ◽  
...  
Keyword(s):  
Transcription Factor ◽  
Mrna Expression ◽  
Neurotrophic Factor ◽  
Infarct Volume ◽  
Brain Derived Neurotrophic Factor ◽  
Binding Activity ◽  
Experimental Stroke ◽  
Enzyme Linked Immunosorbent Assay ◽  
Local Inflammation ◽  
Mobility Shift

This study was aimed to investigate whether brain-derived neurotrophic factor (BDNF) can modulate local cerebral inflammation in ischemic stroke. Rats were subjected to ischemia by occluding the right middle cerebral artery (MCAO) for 2 hours. Rats were randomized as control, BDNF, and antibody groups. The local inflammation was evaluated on cellular, cytokine, and transcription factor levels with immunofluorescence, enzyme-linked immunosorbent assay, real-time qPCR, and electrophoretic mobility shift assay, respectively. Exogenous BDNF significantly improved motor-sensory, sensorimotor function, and vestibulomotor function, while BDNF did not decrease the infarct volume. Exogenous BDNF increased the number of both activated and phagocytotic microglia in brain. BDNF upregulated interleukin10 and its mRNA expression, while downregulated tumor necrosis factor α and its mRNA expression. BDNF also increased DNA-binding activity of nuclear factor-kappa B. BDNF antibody, which blocked the activity of endogenous BDNF, showed the opposite effect of exogenous BDNF. Our data indicated that BDNF may modulate local inflammation in ischemic brain tissues on the cellular, cytokine, and transcription factor levels.

scholarly journals Association of brain derived neurotrophic factor (BDNF) with inflammation in psoriasis

2020 ◽  
Vol 11 (6) ◽  
pp. 72-76
Author(s):  
Hamidraza Moqaddasi ◽  
Ashok Kumar Dubey ◽  
Shitij Goel ◽  
Suparna Dubey   ◽  
Gopi Krishna Maddali
Keyword(s):  
Plaque Psoriasis ◽  
Neurotrophic Factor ◽  
Brain Derived Neurotrophic Factor ◽  
Sensory Innervation ◽  
Enzyme Linked Immunosorbent Assay ◽  
Inflammatory Disorder ◽  
Healthy Controls ◽  
Severe Plaque Psoriasis ◽  
Chronic Inflammatory Disorder ◽  
Organ Systems

Background: Psoriasis is a common immune mediated chronic inflammatory disorder characterized by involvement of skin and other organ systems. Brain derived neurotrophic factor (BDNF) which has various roles in the nervous system, is also involved in cutaneous sensory innervation. Apremilast is a relatively new drug indicated for moderate-to-severe plaque psoriasis and psoriatic arthritis. Aims and Objective: The present study aimed to explore the BDNF levels in moderate to severe plaque psoriasis and analyse the variation in the levels, if any, in response to apremilast therapy. Materials and Methods: Blood samples from patients of psoriasis (n=24), of either sex and age ≥18 years suitable to be prescribed apremilast as standard treatment, were taken on initial and subsequent follow up visit after two months of therapy. Sample from matched controls were also evaluated. Enzyme-linked immunosorbent assay (ELISA) kit (QUAYEE-BIO) and microplate reader (at 450 nm) were used to determine BDNF values. Sample concentrations in each plate were calculated from standard curves and dilution factors. Results: The BDNF values in healthy controls had a mean of 25.14 ± 14.21 ng/mL. The baseline values in the patients had a mean of 72.49± 9.05 ng/mL. The values in the patients after apremilast therapy had a mean of 63.60± 9.53 ng/mL. Conclusion: BDNF levels are significantly increased in patients with moderate to severe plaque psoriasis. Apremilast therapy significantly reduced the raised BDNF levels in such patients, though the reduced level was still significantly higher than the levels in normal healthy controls. Rather than being linked to any neurobehavioral component, the BDNF levels predominantly appear to be linked to the underlying inflammation in psoriasis.

Sign in / Sign up

Export Citation Format

Share Document